Phase 2 COPD Trial, Recruiting NCT07477600 Sponsor: Shenzhen Geno-Immune Medical Institute Condition: COPD
Back to Copd

Phase 2 COPD Trial, Recruiting

NCT07477600
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand the study plan and are willing to sign a written consent form agreeing to take part.
  • People aged between 40 and 80 years old, of any gender.
  • People who have been diagnosed with moderate to severe COPD (a serious lung condition affecting breathing), classified as GOLD Grade II to IV under international COPD guidelines.
  • People who have been regularly using standard COPD medications for more than 3 months, with their condition having been stable for at least 4 weeks.
  • People whose COPD has not responded well enough to standard medical treatments.
  • People with a life expectancy of more than 6 months.
  • People who have not smoked for at least six months before joining, and who are willing to remain smoke-free throughout the entire study period.

Who may not be able to join:

  • People who have other serious lung conditions alongside COPD, such as asthma, active tuberculosis, bronchiectasis, pulmonary embolism, interstitial lung disease, or pulmonary hypertension.
  • People who have had lung surgery (such as removal of part or all of a lung, or lung volume reduction surgery) or certain airway procedures within the past 12 months.
  • People who have needed breathing support through a machine (invasive or non-invasive ventilation) in the past 4 weeks, or who have had a moderate to severe COPD flare-up in the past 4 weeks.
  • People who test negative for HIV, hepatitis C (HCV), or syphilis (confirm with trial site regarding how this criterion is applied).
  • People who have a history of cancer or who are currently being treated for cancer.
  • People who have an autoimmune disease that requires long-term use of steroid or immune-suppressing medications.
  • People with poorly controlled diabetes (fasting blood sugar above 10.0 mmol/L) or other serious metabolic conditions.
  • People with a history of alcohol or drug abuse, or a mental health condition that would make it difficult to follow the study requirements.
  • People who are pregnant or breastfeeding.
  • People who are unable or unwilling to follow the study schedule and procedures.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 0755-86573763

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shenzhen Geno-Immune Medical Institute
Registry
ClinicalTrials.gov
Start date
10 March 2026
Est. completion
31 March 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of patients with adverse events.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov